ASCO Genitourinary Cancers Symposium
ASCO GU 2022 Survival Outcomes and Characterization of Patients With mCSPC Undergoing Intensified ADT Who Do Not Achieve an Optimal PSA Response
By
ASCO Genitourinary Cancers Symposium
FEATURING
Nicolas Sayegh
By
ASCO Genitourinary Cancers Symposium
FEATURING
Nicolas Sayegh
Login to view comments.
Click here to Login